November 05, 2013
A Delaware federal judge on Tuesday handed victory to Bristol-Myers Squibb Co. in its battle to assert its patent on its HIV treatment Sustiva against generic drugmakers Mylan Pharmaceuticals Inc. and Matrix Laboratories Ltd., finding a generic version of the drug would infringe the patent.